有意义的患者代表参与，为加拿大癌症药物资助决策提供信息：泛加拿大肿瘤药物评审中患者代表的观点。
Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
机构信息
Pharmacoeconomics Research Unit, Cancer Care Ontario; Canadian Centre for Applied Research in Cancer Control; Institute for Health Policy, Management and Evaluation, University of Toronto; and Centre for Excellence in Economic Analysis Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON.
Department of Philosophy, University of Leth-bridge, Lethbridge, AB.
出版信息
Curr Oncol. 2014 Oct;21(5):263-6. doi: 10.3747/co.21.2128.
In this interview with the patient representatives on the Expert Review Committee (perc) of the Pan-Canadian Oncology Drug Review (pcodr), those representatives offer their views about how to be a valuable contributing member of Canada's national cancer drug funding recommendation committee. The article seeks to inform readers, and especially clinicians, about pcodr from the perspective of the patient representatives.
在这次对加拿大肿瘤药物评审专家组（perc）中患者代表的采访中，这些代表分享了他们对于如何成为加拿大国家癌症药物资助推荐委员会有价值的一员的看法。本文旨在从患者代表的角度让读者，特别是临床医生，了解 pcodr。
Zotero 插件